Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Fig. 4

Efficacy of H5B14-based ADCS in vitro on cell viability and its association with levels of RON expression: a Effect of H5B14-based ADCs on cancer cell viability. H358 cells (8000 cells per well in a 96-well plate in triplicate) were treated with different amounts of H5B14-MMAE or H5B14-DCM for 72 h. Cell viability was determined by the MTT assay. b Correlation between levels of RON expression and efficacy of H5B14-based ADCs. Cell viability IC50 values from a panel of 15 cancer cell lines expressing variable levels of RON were plotted with different numbers of RON expressed per cell. H5B14-based ADCs at the amount below 5 μg per ml to achieve an IC50 value was used as the effective dose to determine the required receptor number to reach the EC95 value. The IC50 values for cell viability from individual groups were calculated using the GraphPad Prism 7 software. Results shown here are from one of two experiments with similar results

Back to article page